| HS Code | 940742 |
| Chemical Name | L-Leucine Methyl Ester Hydrochloride |
| Cas Number | 6307-83-1 |
| Molecular Formula | C7H16ClNO2 |
| Molecular Weight | 181.66 g/mol |
| Appearance | White crystalline powder |
| Melting Point | 145-150 °C |
| Optical Rotation | [α]20/D +14.5° (c=1, methanol) |
| Solubility | Soluble in methanol, ethanol, water and DMF; insoluble in ether |
| Storage Conditions | Store at -20 °C under inert atmosphere, protect from moisture |
| Purity | ≥98% |
As an accredited L-Leucine Methyl Ester Hydrochloride factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | L-Leucine Methyl Ester Hydrochloride, 25 g, supplied in a sealed amber glass bottle with desiccant for purity preservation. |
| Container Loading (20′ FCL) | 20′ FCL container loading: 25 kg fiber drums on pallets, approximately 20 metric tons per container, secured with dunnage for L-Leucine Methyl Ester Hydrochloride. |
| Shipping | L-Leucine Methyl Ester Hydrochloride is typically shipped at ambient temperature in sealed, moisture-resistant containers. Avoid prolonged heat and humidity. For long-term stability, store refrigerated after receipt. Ensure compliance with local regulations for non-hazardous, non-biological chemical transport. |
| Storage | Store L-Leucine Methyl Ester Hydrochloride in a tightly sealed container in a cool, dry, well-ventilated area, protected from moisture, light, and heat. Avoid contact with strong oxidizing agents and acids. Keep at room temperature or under refrigeration per label, ensuring stable storage to preserve purity. |
| Shelf Life | Stable for two years when stored sealed in a cool, dry place, protected from moisture and light. |
At the 50–200 L pilot scale, L-leucine methyl ester hydrochloride is charged as the C-terminal protected monomer in solution-phase assembly of leucyl dipeptides and tripeptides. The hydrochloride salt suppresses premature nucleophilic attack during storage, but it must be neutralized before coupling. In a representative protocol, 1.0–1.05 equivalents of diisopropylethylamine are added to a suspension of the salt in anhydrous N,N-dimethylformamide at −5 to 0 °C under a nitrogen sweep, followed by addition of an N-protected amino acid active ester. Coupling with EDC·HCl/HOBt in dichloromethane at 0–5 °C for 12–16 h is employed when the N-protecting group is Boc; HATU/DIPEA in DMF at −10 to 0 °C for 2–4 h is preferred for Fmoc systems. The process is monitored by TLC and quenched with 10% citric acid, then extracted with ethyl acetate and washed with 5% sodium bicarbonate. Residual ester and leucyl acid are quantified by HPLC on a C18 column, 250 mm × 4.6 mm, 5 µm, with water/acetonitrile/0.1% trifluoroacetic acid at 1.0 mL/min and UV detection at 214 nm. For peptide APIs, the release envelope includes residual solvents according to ICH Q3C and residual water by Karl Fischer titration. Racemization is the main process risk: excess diisopropylethylamine above 1.2 equivalents or internal coupling temperatures above 15 °C increase D-Leu diastereomer formation. Chiral HPLC using a Chiralpak AD-H column with hexane/2-propanol/trifluoroacetic acid 90:10:0.1 is used to reject batches exceeding 0.5% D-enantiomer. Published data for specific batch-to-batch variance in contract peptide manufacturing is limited, but process-control records uniformly indicate anhydrous solvent handling and absence of free HCl after neutralization are critical.
| Activation system | Solvent | Temperature range | Reaction time | Process note |
|---|---|---|---|---|
| EDC·HCl / HOBt | Dichloromethane | 0–5 °C | 12–16 h | Preferred for Boc-protected amino acids; urea by-products removed by aqueous extraction. |
| HATU / DIPEA | N,N-Dimethylformamide | −10 to 0 °C | 2–4 h | High reactivity for Fmoc systems; lower epimerization at subzero temperature. |
| T3P / N-methylmorpholine | Ethyl acetate | 0–5 °C | 8–12 h | Scale-friendly work-up; slower coupling but low racemization. |
When cell therapy manufacturers remove monocytes and macrophages from peripheral blood mononuclear cell preparations, L-leucyl methyl ester hydrochloride is often introduced as a selective lytic agent. The compound is reconstituted in serum-free RPMI 1640 and adjusted to pH 7.2 before filtration through a 0.22 µm PES membrane. A working concentration of 5 mM is applied to PBMC suspensions at 37 °C in 5% CO₂ for 30–45 min with gentle agitation. Esterase-active lysosomes in phagocytic cells hydrolyze the methyl ester, generating free leucine and increasing intralysosomal osmolality; osmotic swelling and lysosomal rupture follow. Cells without high lysosomal esterase activity are comparatively spared, but prolonged exposure above 60 min reduces natural killer cell recovery. The hydrochloride content influences medium osmolality; therefore stock solutions are prepared at 100 mM in phosphate-buffered saline and diluted immediately before use to avoid precipitation. Published data for specific GMP cell product configurations is limited.
Reduction of L-leucine methyl ester hydrochloride with lithium aluminum hydride or sodium bis(2-methoxyethoxy)aluminum hydride yields L-leucinol, the immediate precursor to 4-isobutyl-substituted oxazolines. Cyclocondensation with dimethylmalonyl dichloride or 2,2-dimethylmalononitrile forms the bis(oxazoline) backbone used in copper-catalyzed asymmetric cyclopropanation and allylic alkylation. The methyl ester hydrochloride starting material must be completely reduced; residual ester is carried through to the ligand as an ester-oxazoline impurity that is difficult to remove by column chromatography. Process-scale batches are quenched at −5 to 0 °C, filtered through Celite, and distilled under reduced pressure to isolate L-leucinol. The free amino alcohol is stored under nitrogen because oxidation to leucinal or leucine lowers enantiomeric purity. Chiral HPLC with Chiralpak AD-H and hexane/2-propanol 90:10 is used to monitor enantiomeric excess. Published data for industrial-scale asymmetric catalysis with this particular ligand class is limited; most published data derive from benchtop screening. Incompatibility with strong mineral acids and acid chlorides requires Schlenk-line handling.
Leucinal-containing serine and cysteine protease inhibitor intermediates are another downstream segment. N-protected L-leucine methyl ester hydrochloride is converted to the corresponding N-protected L-leucinal by low-temperature reduction with diisobutylaluminum hydride in anhydrous tetrahydrofuran at −70 to −78 °C. The aldehyde is not stable under acidic extraction conditions and is handled as the hemisulfite adduct or reduced further to the alcohol. Batch-to-batch color formation is controlled by keeping the reduction temperature below −65 °C; excursions above −60 °C result in over-reduction to leucyl alcohol and loss of chiral integrity. Reactors used for this chemistry at pilot scale are glass-lined, with external circulation cooling capable of holding −75 °C for 6–8 h. No aqueous work-up is used; the reaction is quenched with 10% citric acid at −20 °C after the product has been stabilized. HPLC with chiral stationary phases and on-line LC-MS are used to confirm the absence of leucine and leucyl acid. The high chloride content of the starting salt, if not removed before reduction, contributes to aluminum complex formation and poor filtration. Published data for specific production-scale batches of this configuration is limited.
Short-chain cosmetic peptide programs utilize L-leucine methyl ester hydrochloride as the leucine input when the C-terminal methyl ester must remain intact until final saponification. The hydrochloride salt is converted to the free amine with a tertiary amine base prior to coupling with palmitoyl- or acetyl-protected amino acids. The methyl ester group remains on the C-terminus until the final saponification step, which is carried out at pH 10–11 with lithium hydroxide in tetrahydrofuran/water at 0–5 °C. Chloride carryover into the final peptide is minimized by organic-phase washes with 5% sodium bicarbonate and 10% sodium chloride. Release for cosmetic peptide ingredients follows ISO 22716 manufacturing guidelines; residual solvents are controlled according to ISO 16128 or equivalent supplier specifications. Specific INCI peptide sequences are supplier-confidential, and published data for exact formulation performance is limited.
In analytical method qualification, L-leucine methyl ester hydrochloride is used as a calibration standard for chiral separation of aliphatic amino acid methyl esters. Stock solutions in 0.1 M hydrochloric acid or acetonitrile/water are prepared at 1.0 mg/mL; working calibration curves covering 0.01–1.0 mg/mL are injected on C18 or Chiralpak AD-H columns. The certified appearance, optical rotation, and HPLC area percent are used to qualify detector linearity and injection repeatability. Because the ester is hygroscopic and the hydrochloride salt absorbs water above 60% relative humidity, standard lots are desiccated over phosphorus pentoxide before weighing. Published data for specific pharmacopeia reference standard configurations is limited.
Competitive L-Leucine Methyl Ester Hydrochloride prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
L-Leucine methyl ester hydrochloride is supplied as a white to off-white crystalline solid, assigned CAS Registry Number 7517-19-3 and molecular formula C7H16ClNO2. The formula mass is 181.66 g mol−1. Commercial product models generally appear as H-Leu-OMe·HCl, L-Leu-OMe·HCl, or methyl L-leucinate hydrochloride; these strings are supplier model codes and should be verified against the CAS number and batch certificate. Bulk packaging commonly includes 1 kg and 25 kg HDPE drums with inner polyethylene liners. The salt is freely soluble in water and methanol, soluble in ethanol, and practically insoluble in diethyl ether. The protonated amine and methyl-ester-protected carboxylic acid distinguish it from the parent L-leucine zwitterion and from N-protected leucine derivatives such as Boc-Leu-OH or Cbz-Leu-OH. Its use is confined to synthetic intermediate operations; the material is not a formulated pharmaceutical product.
The principal purpose of the methyl ester protection is to block the carboxyl group while leaving the amino group available for neutralization and subsequent reaction. In comparison with free L-leucine, the hydrochloride salt dissolves readily in water as a salt, and after neutralization the resulting methyl ester partitions into ethyl acetate or dichloromethane. This behavior is used in liquid-liquid extraction processes where the free amino acid would remain in the aqueous phase. The methyl ester group is smaller and less sterically demanding than the ethyl or tert-butyl ester, and this affects hydrolysis kinetics, crystallization, and downstream removal.
The protonated amine prevents direct amide formation in carbodiimide-mediated coupling. Free-basing is therefore required before the material can be used as the amine component. In non-aqueous systems, triethylamine or N-methylmorpholine is added at 1.0–1.05 equivalents relative to the salt. The neutralization is exothermic and is controlled at 0–5 °C in anhydrous dichloromethane or tetrahydrofuran. The free base is not isolated; the resulting suspension is filtered to remove triethylamine hydrochloride and the filtrate is used immediately. In aqueous workup, sodium bicarbonate or potassium carbonate at pH 8.5–9.0 releases the free base into ethyl acetate. Recovery is improved by 3 countercurrent extractions; the organic layer is dried over sodium sulfate and concentrated below 30 °C to limit ester hydrolysis.
The protonated α-ammonium group of amino acid methyl ester hydrochlorides has an approximate pKa of 7.5–8.0, requiring a neutralization base with pKa above 10. Incomplete neutralization leaves hydrochloride salt in the organic phase and reduces coupling efficiency. At pilot scale, the precipitated triethylamine hydrochloride is a crystalline solid that can blind filter media; agitated pressure filters with 5–10 μm polypropylene cloth are used to maintain filtration rate. Liquid-liquid separation is performed in cylindrical vessels with bottom outlet and sight glass; emulsion formation is minimized by avoiding strong alkalinity above pH 9.5, which also accelerates saponification of the methyl ester.
| Parameter | Typical limit | Method / standard |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual examination; batch record control |
| Identification | FTIR spectrum conforms to reference | USP <197> |
| Assay | ≥98.0% area | HPLC, USP <621>; detection at 210 nm |
| Chloride content | 19.0–20.0% w/w | Argentometric titration, USP <541> |
| Water content | ≤0.5% w/w | Karl Fischer, USP <921> / ISO 760 |
| Specific rotation [α]20D | +14.5° to +15.5° (c=2, methanol) | Polarimetry, Ph. Eur. 2.2.7 |
| Heavy metals | ≤10 ppm | ICP-MS, USP <233> |
| Residual solvents | Methanol ≤3000 ppm; tetrahydrofuran ≤720 ppm | USP <467> Option 2 |
| Sulfated ash | ≤0.1% w/w | USP <281> |
The tabulated values are representative compilation criteria for commercial release; individual batch certificates govern actual acceptance limits. The HPLC procedure typically employs a C18 column with UV detection at 210 nm and a mobile-phase gradient of 0.1% trifluoroacetic acid in water and acetonitrile. Peak purity is evaluated by diode-array detection, with a single main peak accounting for ≥98.0% of total area. Chloride content is determined by potentiometric argentometric titration with 0.1 M silver nitrate. Specific rotation is measured in a 1 dm polarimeter cell at 20 °C at the sodium D-line. These methods distinguish the salt from L-leucine and from the free leucine methyl ester during incoming inspection.
In the preparation of L-leucine N-carboxyanhydride, the hydrochloride is slurried in anhydrous tetrahydrofuran at 0–5 °C under nitrogen, and triethylamine is added over 20–30 min. Triphosgene at 0.35–0.40 equivalents is then introduced as a tetrahydrofuran solution while maintaining internal temperature below 25 °C. The reaction is monitored by FTIR for appearance of NCA carbonyl bands at approximately 1830 cm−1 and 1790 cm−1. The byproduct triethylamine hydrochloride is removed by filtration under inert atmosphere. The filtrate is concentrated at ≤30 °C under reduced pressure, and the NCA is crystallized from ethyl acetate/n-heptane. Residual water above 0.1% in the starting salt reduces NCA yield because water hydrolyzes both the NCA product and phosgene equivalents.
For ring-opening polymerization, Leu NCA is dissolved in anhydrous N,N-dimethylformamide at 0.1–1.0 M. Initiation with n-hexylamine at monomer/initiator ratios between 20:1 and 100:1 produces poly(L-leucine) blocks. The reaction is followed by disappearance of the NCA carbonyl bands; final dispersity depends on residual water, solvent dryness, and initiator purity. For manufacturing campaigns where NCA stability controls molecular weight distribution, the hydrochloride is therefore purchased as a non-polymerizable dry solid and converted to the NCA immediately before polymerization.
After neutralization, the methyl ester of L-leucine is used as the amine component in solution-phase peptide synthesis. Typical coupling reagents include N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride with 1-hydroxybenzotriazole in N,N-dimethylformamide at 0–5 °C, or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate with N,N-diisopropylethylamine for hindered substrates. The hydrochloride counterion of the amino component is neutralized before coupling; otherwise the acidic proton consumes the coupling reagent. After chain extension, the methyl ester is removed with lithium hydroxide in tetrahydrofuran/water 1:1 at 0 °C or with sodium hydroxide in methanol. These conditions are selected to limit α-carbon racemization. At process scale, the saponification is conducted in a jacketed reactor with pH probe; the endpoint is indicated by stabilization at pH 10.5–11.0 and disappearance of the ester carbonyl stretch at approximately 1735 cm−1 by process FTIR.
The methyl ester cleavage step is faster than the corresponding ethyl ester cleavage, which is exploited when a C-terminal acid must be revealed under mild base. If the C-terminus must remain blocked during repeated base treatments, the tert-butyl ester is preferred; if it must be removed by hydrogenolysis under neutral conditions, the benzyl ester is preferred. The hydrochloride salt of the methyl ester is not normally used in solid-phase peptide synthesis because the C-terminus is not attached to the resin in its protected methyl ester form, but it is used to prepare leucine building blocks and NCA monomers for subsequent polymerizations.
The methyl ester is removed under basic or nucleophilic conditions more rapidly than the ethyl ester, and it remains intact under the acid conditions that cleave the tert-butyl ester. The tert-butyl ester is selected when the C-terminus must survive repeated basic transformations; the benzyl ester is selected when the C-terminus must be released by hydrogenolysis without disturbing acid- or base-labile groups elsewhere. The hydrochloride salt rather than the free base is preferred for storage because the protonated amine reduces volatile free-amine loss and improves batch-to-batch consistency in dry solid handling.
| Derivative | Formula mass | Ester deprotection conditions | Typical use |
|---|---|---|---|
| L-Leucine methyl ester HCl | 181.66 g mol−1 | LiOH/THF/H₂O or NaOH/MeOH | NCA synthesis, solution peptides, chiral auxiliaries |
| L-Leucine ethyl ester HCl | 195.69 g mol−1 | NaOH/EtOH or LiOH/THF/H₂O; slower hydrolysis | Peptide intermediates requiring lower ester volatility |
| L-Leucine tert-butyl ester HCl | 223.74 g mol−1 | 50% TFA/DCM or HCl/dioxane | Base-resistant C-terminal protection |
| L-Leucine benzyl ester HCl | 257.76 g mol−1 | H₂/Pd/C hydrogenolysis | Orthogonal deprotection sequences |
| L-Leucine free base | 131.17 g mol−1 | No ester cleavage required | Direct amino acid chemistry, buffer preparation |
Compared with the free amino acid, the hydrochloride salt offers organic-phase extractability after neutralization and a protected carboxyl group for regioselective amine chemistry. Compared with the ethyl ester hydrochloride, the methyl ester generally hydrolyzes faster and has a smaller process mass. Compared with the tert-butyl ester hydrochloride, the methyl ester tolerates acidic conditions but is removed by base; this is the key process difference when designing a synthetic route with multiple ester or acid-labile groups.
Quality agreements for cGMP intermediates typically require the supplier to report residual solvents under USP <467> Option 2, elemental impurities under USP <233>/ICH Q3D, and water content by ISO 760. The material is manufactured under ISO 9001:2015 and can be supplied with a certificate of analysis that includes batch-specific chromatographic and titration data. EU REACH registration is required for EU manufacturing or import at ≥1 t/a; downstream users should confirm that their use is covered by the registered dossier. The substance is not generally classified as dangerous goods for transport in dry powder form; however, the safety data sheet should be checked for local hazard classifications and dust control requirements.
The salt is hygroscopic and should be stored at 2–8 °C in tightly closed containers. At relative humidity above 60%, the powder can form a crust or paste. In production suites, drums should be opened under nitrogen or in a dry room; after each withdrawal, the container should be purged and resealed. Prior to use in NCA synthesis, the material may be dried at 40 °C under vacuum for 12 h; this reduces free water but does not remove bound HCl. Heating above 60 °C should be avoided because the methyl ester can hydrolyze or release methanol in the presence of moisture. Aqueous solutions should be prepared just before use and held at 0–5 °C where possible.
Incompatibilities include strong bases, which will saponify the methyl ester if added abruptly, and strong oxidizing agents. The hydrochloride salt should not be milled in ungrounded equipment without dust control; fine dust can be irritating to the respiratory tract. Storage beyond the retest date should be supported by batch-specific stability data and re-qualification against the original release specification.